Details for Patent: 9,006,281

Which drugs does patent 9,006,281 protect, and when does it expire?

Patent 9,006,281 protects IBSRELA and is included in one NDA.

This patent has thirty-nine patent family members in twenty-two countries.

Summary for Patent: 9,006,281

Title:	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Abstract:	The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure
Inventor(s):	Noah Bell, Christopher Carreras, Dominique Charmot, Jeffrey W Jacobs, Michael Robert Leadbetter, Marc Navre
Assignee:	Ardelyx Inc
Application Number:	US13/826,186
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,006,281
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,006,281

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes						METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR

International Family Members for US Patent 9,006,281

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009334511
Brazil	PI0923861
Canada	2748607
China	102333759